Fig. 1: RSK1 is elevated in treatment-naïve and inhibitor-resistant FLT3-ITD AML. | Blood Cancer Journal

Fig. 1: RSK1 is elevated in treatment-naïve and inhibitor-resistant FLT3-ITD AML.

From: RSK1 dependency in FLT3-ITD acute myeloid leukemia

Fig. 1

A RPS6KA1 expression in patients with positive (n = 158) or negative (n = 511) FLT3-ITD consensus calling from the BeatAML2 cohort. B Immunoblot of Ba/F3 cells transduced with FLT3-ITD, FLT3 D835Y, or GFP control plasmids. C scRNA-seq re-analysis of the myeloid population from serial gilteritinib treated FLT3-mutated AML patient samples from GSE199333. Samples were denoted as “sensitive” (n = 16,810 cells) or “resistant” (n = 30,993 cells) per source publication. D Venn diagram of shared DEGs upregulated in samples from three AML patients that developed resistance to gilteritinib compared to pre-treatment samples from (C). E Hallmark GSEA of shared 244 DEGs from gilteritinib-resistant patients from (D). F Expression dot plot showing expression changes of FLT3 and RPS6KA1 across gilteritinib treatment timepoints in patients who were sensitive or became resistant to treatment.

Back to article page